多omics分析显示,阿司匹林与阿尔茨海默病风险降低有关
medRxiv : the preprint server for health sciences
|April 29, 2025
概括
阿司匹林可能有助于预防阿尔茨海默病 (AD). 这项研究结合了遗传和现实世界的数据,确定阿司匹林是治疗阿尔茨海默病的有希望的药物. 建议进行进一步的临床试验.
科学领域:
- 神经科学和药理学 神经科学和药理学
- 遗传学和基因组学 在
- 数据科学和生物信息学
背景情况:
- 迫切需要安全有效的阿尔茨海默病 (AD) 疗法.
- 越来越多的人对药物用于AD治疗和预防的重用感兴趣.
- 整合多学科和临床数据,以实现新型治疗发现.
研究的目的:
- 调查阿尔茨海默病 (AD) 药物重用机会.
- 确定能够逆转AD相关基因表达变化的化合物.
- 评估阿司匹林作为阿兹海默症的潜在治疗剂.
主要方法:
- 使用GTEx和MiGA数据集进行全转录组关联研究 (TWAS).
- 查询连接地图 (CMap) 数据库的候选药物.
- 分析来自EHR (VUMC,我们所有人) 和索赔数据 (MarketScan) 的现实数据.
主要成果:
- 阿司匹林被确定为最有前途的小分子化合物用于AD重定位.
- 65岁之前使用阿司匹林与发生AD的风险降低有关 (HR=0.76,P=0.001).
- 在索赔数据中,在AD病例中,阿司匹林暴露的几率显著降低 (OR=0.32,P<0.001).
结论:
- 证明了将遗传和临床数据整合为药物重新用途的价值.
- 突出阿司匹林作为阿尔茨海默病的有希望的重定向候选人.
- 在临床试验中要求进一步调查阿司匹林用于AD预防和治疗.
相关概念视频
Genome-wide Association Studies-GWAS
12.0K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.0K
Alzheimer's Disease: Overview
315
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
315
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128


